"Betaxolol: long-term therapeutic efficacy and safety in glaucoma patients with chronic obstructive lung diseases".

The authors refer their experience with Betaxolol in the long-term treatment of open-angle glaucoma. The parameters considered were: ocular pressure, biomicroscopy of the eye anterior segment, systemic blood pressure, heart rate and static spirometric values ( prior to and after aerosol administration of the data obtained it was shown that betaxolol induces a long-term marked ocular hypotensive action ( 5 years of observation) without modifying lung function ( in asthmatic glaucomatous patients) and cardiocirculatory conditions. No adverse reactions, both topical and systemic, were ever noted.